iCo Therapeutics Inc. (iCo) is a Canadian biotechnology company focused on the identification, development and commercialization of drug candidates to treat sight threatening and life threatening diseases through a business model. The Company focuses on in-licensing drug candidates with a clinical history and redose, reformulate and develop drug candidates for the treatment of sight-threatening conditions, such as diabetic macular edema (DME) and severe allergic conjunctivitis and life threatening diseases such as severe systemic fungal infections. Its in-license three product candidates are iCo-007, iCo-008 and an Oral Amphotericin B Delivery System (formerly iCo-009), which is under development. On February 22, 2011, iCo announced the completion of Phase II clinical supply manufacturing of ICo-007. On September 26, 2011, iCo announced a research collaboration agreement with Juvenile Diabetes Research Foundation (JDRF) for the Phase II clinical trial investigation of iCo-007 in DME.